Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Vanderbilt University |
---|---|
Information provided by: | Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00178828 |
The purpose of this study is to understand changes in brain chemical signals when people take antidepressants called sertraline (Zoloft®) and bupropion (Wellbutrin SR, Zyban ®). Spinal fluid is used to measure chemical levels of dopamine, serotonin, and other chemicals thought to be involved in depression. The study has potential to help understand and treat depression.
Condition | Intervention | Phase |
---|---|---|
Depression |
Drug: sertraline Drug: bupropion |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment |
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Tennessee | |
Vanderbilt University Medical Center | |
Nashville, Tennessee, United States, 37212 |
Principal Investigator: | Ronald M Salomon, MD | Vanderbilt University |
Study ID Numbers: | 000373, 5 K23 MH001828-03 |
Study First Received: | September 12, 2005 |
Last Updated: | August 27, 2007 |
ClinicalTrials.gov Identifier: | NCT00178828 |
Health Authority: | United States: Food and Drug Administration |
Depression antidepressant SSRI |
Depression Mental Disorders Bupropion Mood Disorders |
Sertraline Depressive Disorder Serotonin Behavioral Symptoms |
Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Serotonin Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs |
Psychotropic Drugs Serotonin Uptake Inhibitors Central Nervous System Agents Pharmacologic Actions Antidepressive Agents |